IMP3与p16在宫颈癌中的表达及其临床意义

doi:10.3760/cma.j.issn.1673-422X.2014.12.020

摘要/Abstract

摘要： 目的检测胰岛素样生长因子Ⅱ mRNA 结合蛋白3（IMP3）与p16在宫颈癌的表达，探讨其临床意义。方法采用免疫组织化学Envision二步法检测67例宫颈癌、58例宫颈上皮内瘤变及15例正常宫颈组织中IMP3及p16的表达情况。结果IMP3在宫颈癌组织细胞质中表达，阳性表达率85.07%(57/67)，显著高于宫颈上皮内瘤变12.07%（7/58； χ2=66.32，P＜0.05）及正常宫颈组织的阳性表达率0（0/15； χ2=44.38，P＜0.05）。IMP3在宫颈腺癌及宫颈鳞状细胞癌中均呈高表达，两者差异无统计学意义(χ2=0.35，P＞0.05 )。p16在宫颈癌组织细胞质和细胞核均有表达，阳性表达率为 83.58%（56/67），显著高于宫颈上皮内瘤变41.37%（24/58； χ2=24.85，P＜0.05）及正常宫颈组织的阳性表达率0（0/15； χ2=42.61，P＜0.05）。结论IMP3与p16在宫颈癌中高表达，可能作为预测宫颈癌转移潜能及预测宫颈上皮内瘤变进展为宫颈浸润癌的指标。

关键词: 基因, p16, 宫颈肿瘤, 胰岛素样生长因子Ⅱ mRNA 结合蛋白3

Abstract: ObjectiveTo detect the expression of insulinlike growth factor Ⅱ mRNAbinding protein 3 (IMP3) and p16 in cervical carcinoma and investigate their clinical significance. MethodsImmunohistochemical Envision method was used to detect the expression of IMP3 and p16 proteins in 67 cases of carcinoma of the uterine cervix, 58 cases of cervical intraepithelial neoplasia (CIN) and 15 cases of normal cervical epithelium. ResultsIMP3 was mainly dedected in the cytoplasm, whose positive expression rate was 85.07%（57/67）in cervical carcinoma, 12.07% (7/58) in CIN (χ2=66.32, P＜0.05) and 0 (0/15) in cervical epithelium (χ2=44.38, P＜0.05). No significance variations of the expression of IMP3 were observed in cervical adenocarcinoma and squamous cell carcinoma (χ2=0.35, P＞0.05). p16 was found both in nucleus and cytoplasm of cervical carcinoma, whose expression rate was 83.58% (56/67), higher than 41.37% (24/58) in CIN (χ2=24.85, P＜0.05) and 0 (0/15) in cervical epithelium (χ2=42.61, P＜0.05). ConclusionExpression of IMP3 and p16 is high in cervical carcinoma, maybe can be used as a potential biomarker of metastasis and progression.

Key words: Genes, p16, Uterine cervical neoplasms, Insulin-like growth factor Ⅱ mRNA-binding protein 3

冯彦丽. IMP3与p16在宫颈癌中的表达及其临床意义[J]. 国际肿瘤学杂志, 2014, 41(12): 946-949.

FENG Yan-Li. Expression and clinical significance of IMP3 and p16 in cervical carcinoma[J]. Journal of International Oncology, 2014, 41(12): 946-949.

参考文献

［1］ Parkin DM. The global health burden of infectionassociated cancers in the year 2002［J］. Int J Cancer, 2006, 118(12):30303044. ［2］董岩, 程静新, 宫颈癌及宫颈上皮内瘤变相关危险因素分析［D］. 新疆, 新疆医科大学. 2010:1213. ［3］ Wagner M, Kunsch S, Duerschmied D, et al. Transgenic over expression of the oncofetal RNA binding protein KOC leads to remodeling of the exocrine pancreas［J］. Gastroenterology, 2003, 124(7): 19011914. ［4］ Lu D, Yang X, Jiang NY, et al. IMP3, a new biomarker to predict progressi on of cervical intraepithelial neoplasiain to invasive cancer［J］. Am J Surg Pathol, 2011, 35(11): 16381645．［5］ Subhawong AP, Subhawong T, Nassar H, et al. Most basallike breast carcinomas demonstrate the same Rb-/pl6+ immunophenotype as the HPVrelated poorly differentiated squamous cell carcinomas which they resemble morphologically［J］. Am J Surg Pathol, 2009, 33(2): 163175. ［6］ Zushi Y, NarisawaSaito M, Noguchi K, et al. An in vitro multistep carcinogenesis modelfor both HPVpositive and negative human oral squamous cell carcinomas［J］. Am J Cancer Res, 2011, 1(7):869881. ［7］ Zheng T, Holford TR, Ma Z, et al. The continuing increase in adenocarcinoma of the uterine cervix: a birth cohort phenomenon［J］. Epidemiology, 1996, 25(2): 252258. ［8］ Slosar M, Vohra P, Prasad M, et al. Insulinlike growth factor Mrna binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors［J］. Endocr Pathol, 2009, 20(3):149157. ［9］ Walter O, Prasad M, Lu S, et al. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype［J］. Hum Pathol, 2009, 40(11): 15281533. ［10］ Noske A, Faggad A, Wirtz R, et al. IMP3 expression in human ovarian cancer is associated with improved survival［J］. Int J Gynecol Pathol, 2009, 28(3): 203210. ［11］ Vikesaa J, Hansen TV, Jonson L, et al. RNAbinding IMPs promote celladhesion and in vadopodia formation［J］. Embo J, 2006, 25(7): 14561468. ［12］杨会杰, 宋金凤. IMP3、p53在宫颈癌中的表达及临床意义. 现代妇产科进展［J］. 2013, 22(4): 320324. ［13］武海英, 魏利, 史惠蓉. P16及pRb在宫颈癌中的表达及意义［J］. 中华实用诊断与治疗杂志, 2011, 25(10): 976978.

[1]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.
[2]	张露, 蒋华, 林州, 马辰莺, 徐晓婷, 王利利, 周菊英. 免疫检查点抑制剂治疗复发转移性宫颈癌的疗效及预后分析[J]. 国际肿瘤学杂志, 2023, 50(8): 475-483.
[3]	吴佳丽, 张佳慧, 张萍, 肖昕悦, 李睿, 张红宇. Bcl-2 BH4选择性抑制剂BDA-366抑制NK/T细胞淋巴瘤细胞的机制研究[J]. 国际肿瘤学杂志, 2023, 50(7): 413-418.
[4]	吕璐, 孙鹏飞. 肠道菌群与宫颈癌[J]. 国际肿瘤学杂志, 2023, 50(6): 373-376.
[5]	李彬, 张桂芳, 周林静, 杨小冬, 何秋立, 贾思思, 黄普超, 梁嘉欣. 三阴性乳腺癌中PIK3CA基因状态与临床特征及预后的关系[J]. 国际肿瘤学杂志, 2023, 50(5): 263-267.
[6]	刘博翰, 黄俊星. 溶质载体SLC7A5及SLC7A11基因在恶性肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(5): 280-284.
[7]	刘玉杰, 赵志强, 王子琤. 早期结直肠癌患者外周血单个核细胞中TOP2A、ERBB2的水平及其诊断价值[J]. 国际肿瘤学杂志, 2023, 50(12): 717-722.
[8]	邓莉莉, 段星宇, 李保中. HER2靶向药物及其联合治疗方案在胃及食管胃结合部腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(12): 751-757.
[9]	陈群响, 张晓钰, 张妍, 张凯翔, 李捷, 陈曦. 伊尼妥单抗联合长春瑞滨治疗HER2阳性转移性乳腺癌1例[J]. 国际肿瘤学杂志, 2023, 50(12): 763-765.
[10]	段传菊, 陈真云, 李晓红, 牛洪朋, 李秀敏. 复发宫颈癌免疫治疗1例[J]. 国际肿瘤学杂志, 2023, 50(12): 766-768.
[11]	马雪艳, 鲁历历, 孙鹏飞. 免疫微环境在宫颈癌中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 47-50.
[12]	张露, 周菊英, 马辰莺, 林州. 复发转移性宫颈癌免疫治疗相关进展[J]. 国际肿瘤学杂志, 2022, 49(9): 517-520.
[13]	张子悦, 郑斯豪, 高彦君, 姚颐, 宋启斌. 基于CRISPR/Cas9的基因编辑技术及其在肿瘤治疗中的应用[J]. 国际肿瘤学杂志, 2022, 49(9): 546-549.
[14]	史英侠, 胡莉钧, 于静萍. 免疫检查点抑制剂在复发或转移性宫颈癌治疗中的应用[J]. 国际肿瘤学杂志, 2022, 49(9): 568-571.
[15]	彭琛, 谢印通, 张昕, 谢鹏. 宫颈癌维持治疗研究进展[J]. 国际肿瘤学杂志, 2022, 49(7): 430-435.